Reflect Scientific, Inc. (RSCF)
USD 0.04
(-3.26%)
USD 0.04
(-3.26%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -467.27 Thousand USD | -618.64% |
| 2022 | 90.09 Thousand USD | -89.12% |
| 2021 | 827.8 Thousand USD | 27.16% |
| 2020 | 651 Thousand USD | 434.13% |
| 2019 | -194.83 Thousand USD | 21.71% |
| 2018 | -248.86 Thousand USD | 38.12% |
| 2017 | -402.18 Thousand USD | -59.85% |
| 2016 | -251.6 Thousand USD | 45.3% |
| 2015 | -459.95 Thousand USD | 35.99% |
| 2014 | -718.59 Thousand USD | 20.04% |
| 2013 | -898.68 Thousand USD | 69.14% |
| 2012 | -2.91 Million USD | -311.95% |
| 2011 | -706.92 Thousand USD | -693.44% |
| 2010 | -89.09 Thousand USD | 96.39% |
| 2009 | -2.46 Million USD | -361.51% |
| 2008 | -535.03 Thousand USD | 90.11% |
| 2007 | -5.41 Million USD | -379.45% |
| 2006 | -1.12 Million USD | -1854.31% |
| 2005 | 64.32 Thousand USD | -48.33% |
| 2004 | 124.49 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 98.34 Thousand USD | 342.82% |
| 2024 Q1 | -40.5 Thousand USD | 81.55% |
| 2023 Q3 | 80.89 Thousand USD | 144.75% |
| 2023 FY | -467.28 Thousand USD | -618.64% |
| 2023 Q4 | -219.56 Thousand USD | -371.41% |
| 2023 Q2 | -180.77 Thousand USD | -22.28% |
| 2023 Q1 | -147.83 Thousand USD | -141.13% |
| 2022 Q1 | 206.5 Thousand USD | -42.74% |
| 2022 FY | 90.09 Thousand USD | -89.12% |
| 2022 Q2 | 78.12 Thousand USD | -62.17% |
| 2022 Q3 | -133.22 Thousand USD | -270.52% |
| 2022 Q4 | -61.31 Thousand USD | 53.98% |
| 2021 Q4 | 360.62 Thousand USD | 125.55% |
| 2021 Q3 | 159.88 Thousand USD | -6.38% |
| 2021 Q2 | 170.78 Thousand USD | 25.11% |
| 2021 Q1 | 136.5 Thousand USD | -55.47% |
| 2021 FY | 827.8 Thousand USD | 27.16% |
| 2020 Q3 | 204.18 Thousand USD | 902.53% |
| 2020 Q1 | 165.71 Thousand USD | 195.69% |
| 2020 FY | 651 Thousand USD | 434.13% |
| 2020 Q2 | -25.44 Thousand USD | -115.35% |
| 2020 Q4 | 306.54 Thousand USD | 50.13% |
| 2019 Q2 | -19.56 Thousand USD | -266.6% |
| 2019 Q3 | 3237.00 USD | 116.55% |
| 2019 Q4 | -173.17 Thousand USD | -5449.77% |
| 2019 FY | -194.83 Thousand USD | 21.71% |
| 2019 Q1 | -5336.00 USD | 93.92% |
| 2018 FY | -248.86 Thousand USD | 38.12% |
| 2018 Q4 | -87.71 Thousand USD | -108.27% |
| 2018 Q3 | -42.11 Thousand USD | 80.66% |
| 2018 Q2 | -217.74 Thousand USD | -320.57% |
| 2018 Q1 | 98.72 Thousand USD | 120.92% |
| 2017 Q1 | -2388.00 USD | 99.25% |
| 2017 FY | -402.18 Thousand USD | -59.85% |
| 2017 Q4 | -471.95 Thousand USD | -899.15% |
| 2017 Q3 | 59.05 Thousand USD | 350.85% |
| 2017 Q2 | 13.09 Thousand USD | 648.53% |
| 2016 FY | -251.6 Thousand USD | 45.3% |
| 2016 Q1 | 36.03 Thousand USD | 109.89% |
| 2016 Q4 | -319.66 Thousand USD | -541.06% |
| 2016 Q3 | -49.86 Thousand USD | -160.89% |
| 2016 Q2 | 81.89 Thousand USD | 127.28% |
| 2015 Q1 | -1722.00 USD | 99.77% |
| 2015 FY | -459.95 Thousand USD | 35.99% |
| 2015 Q4 | -364.42 Thousand USD | -693.07% |
| 2015 Q3 | -45.95 Thousand USD | 3.97% |
| 2015 Q2 | -47.85 Thousand USD | -2678.86% |
| 2014 Q3 | -33.47 Thousand USD | -407.77% |
| 2014 FY | -718.59 Thousand USD | 20.04% |
| 2014 Q4 | -753.17 Thousand USD | -2150.31% |
| 2014 Q2 | 10.87 Thousand USD | -80.98% |
| 2014 Q1 | 57.17 Thousand USD | 107.74% |
| 2013 Q2 | -58.66 Thousand USD | 32.32% |
| 2013 Q4 | -738.34 Thousand USD | -4825.58% |
| 2013 Q1 | -86.68 Thousand USD | 96.65% |
| 2013 Q3 | -14.99 Thousand USD | 74.45% |
| 2013 FY | -898.68 Thousand USD | 69.14% |
| 2012 Q3 | -118.77 Thousand USD | -49.08% |
| 2012 Q4 | -2.58 Million USD | -2078.62% |
| 2012 FY | -2.91 Million USD | -311.95% |
| 2012 Q1 | -126 Thousand USD | 62.81% |
| 2012 Q2 | -79.67 Thousand USD | 36.77% |
| 2011 Q2 | -256.94 Thousand USD | -338.8% |
| 2011 Q4 | -338.83 Thousand USD | -544.31% |
| 2011 Q3 | -52.58 Thousand USD | 79.53% |
| 2011 Q1 | -58.55 Thousand USD | 17.86% |
| 2011 FY | -706.92 Thousand USD | -693.44% |
| 2010 Q1 | -31.53 Thousand USD | 95.57% |
| 2010 FY | -89.09 Thousand USD | 96.39% |
| 2010 Q4 | -71.28 Thousand USD | -701.4% |
| 2010 Q3 | 11.85 Thousand USD | 534.87% |
| 2010 Q2 | 1867.00 USD | 105.92% |
| 2009 Q3 | -813.52 Thousand USD | -111.29% |
| 2009 FY | -2.46 Million USD | -361.51% |
| 2009 Q1 | -559.05 Thousand USD | 31.03% |
| 2009 Q2 | -385.03 Thousand USD | 31.13% |
| 2009 Q4 | -711.61 Thousand USD | 12.53% |
| 2008 Q3 | 204.62 Thousand USD | 1.0% |
| 2008 Q2 | 202.58 Thousand USD | 253.86% |
| 2008 Q4 | -810.57 Thousand USD | -496.13% |
| 2008 Q1 | -131.66 Thousand USD | 96.5% |
| 2008 FY | -535.03 Thousand USD | 90.11% |
| 2007 Q4 | -3.75 Million USD | -420.46% |
| 2007 FY | -5.41 Million USD | -379.45% |
| 2007 Q1 | -397.35 Thousand USD | -67.36% |
| 2007 Q2 | -532.62 Thousand USD | -34.04% |
| 2007 Q3 | -722.11 Thousand USD | -35.58% |
| 2006 Q3 | -774.81 Thousand USD | -348.45% |
| 2006 Q1 | 28.06 Thousand USD | 177.25% |
| 2006 Q4 | -237.42 Thousand USD | 69.36% |
| 2006 FY | -1.12 Million USD | -1854.31% |
| 2006 Q2 | -172.77 Thousand USD | -715.61% |
| 2005 Q4 | 10.12 Thousand USD | -82.24% |
| 2005 FY | 64.32 Thousand USD | -48.33% |
| 2005 Q3 | 57 Thousand USD | 2049.32% |
| 2005 Q1 | -5450.00 USD | 0.0% |
| 2005 Q2 | 2652.00 USD | 148.66% |
| 2004 FY | 124.49 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| American Medical Technologies Inc. | 1.16 Million USD | 140.137% |
| Ansell Limited | 129.3 Million USD | 100.361% |
| Ansell Limited | 129.3 Million USD | 100.361% |
| BG Medicine, Inc. | - USD | Infinity% |
| Biotage AB (publ) | 31.13 Million USD | 101.501% |
| BioLife Sciences Inc. | - USD | Infinity% |
| CB Scientific, Inc. | -1.59 Million USD | 70.716% |
| Psykey, Inc. | -797.5 Thousand USD | 41.407% |
| ConvaTec Group Plc | 262.7 Million USD | 100.178% |
| ConvaTec Group Plc | 262.7 Million USD | 100.178% |
| Encision Inc. | -640.78 Thousand USD | 27.077% |
| Golden Valley Development, Inc | -141.81 Thousand USD | -229.51% |
| Hear AtLast Holdings, Inc. | -109.93 Thousand USD | -325.069% |
| Innovative MedTech Inc. | -4.27 Million USD | 89.067% |
| LifePoint, Inc. | -7.49 Million USD | 93.766% |
| Medite Cancer Diagnostics, Inc. | -6.48 Million USD | 92.789% |
| Paradigm Medical Industries, Inc. | 330 Thousand USD | 241.599% |
| QuantRx Biomedical Corporation | - USD | Infinity% |
| Remedent, Inc. | -122.89 Thousand USD | -280.241% |
| SmileDirectClub, Inc. | -241.15 Million USD | 99.806% |
| Sector 10, Inc. | -39.84 Thousand USD | -1072.769% |
| Shandong Weigao Group Medical Polymer Company Limited | 319.6 Million USD | 100.146% |
| SheerVision, Inc. | 155.72 Thousand USD | 400.064% |
| United Health Products, Inc. | -2.42 Million USD | 80.743% |
| Vasamed, Inc. | 4.74 Million USD | 109.853% |
| Wearable Health Solutions, Inc. | -2.29 Million USD | 79.632% |
| Yubo International Biotech Limited | -1.2 Million USD | 61.229% |